Follows people with advanced liver cancer treated with immune checkpoint inhibitors
Observes how long patients with advanced liver cancer live while on immunotherapy.
Plain-language title generated from the registry record
Registry title: Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes
Key facts
- Where
- Sohag, EgyptSee the 2 sites
Where in Egypt
- Sohag university hospitalsSohag, EgyptNo longer taking part
- sSohag oncology centreSohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ahmed Karam Helmy
- Trial code
- NCT07321067
- Record updated
- 6 January 2026
- Original description
the Objectives of this study are:Read full original descriptionShow less
Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes
the Objectives of this study are:
• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.
the main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.
Inclusion: Adults (≥18 years) with radiologically or histologically confirmed advanced HCC; Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab); Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .
Exclusion: Prior liver transplantation; patients with concurrent malignancies other than HCC; Active autoimmune disease requiring systemic immunosuppression; Child-Pugh C liver function.